Skip to main content
Renata Ferrarotto, MD, Oncology, Houston, TX, University of Texas M.D. Anderson Cancer Center

RenataFerrarottoMD

Oncology Houston, TX

Head & Neck Cancer, Thoracic Cancer

Clinical fellow

Dr. Ferrarotto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ferrarotto's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Fc9.2063 (Faculty Center Building)
    Houston, TX 77030
    Phone+1 713-745-6774
    Fax+1 713-792-1220
  • Is this information wrong?

Education & Training

  • University of Campinas Faculty of Medicine
    University of Campinas Faculty of MedicineClass of 2006

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2016 - 2024
  • OK State Medical License
    OK State Medical License 2020 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Risk and Clinical Risk Factors Associated with Late Lower Cranial Neuropathy in Long-Term Oropharyngeal Squamous Cell Carcinoma Survivors  
    Ryan P Goepfert, Stephen Y Lai, Renata Ferrarotto, Erich M Sturgis, JAMA Otolaryngology–Head & Neck Surgery
  • Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019  
    Renata Ferrarotto, MD, JAMA Oncology
  • PI3‐Kinase Pathway Biomarkers in Oral Cancer and Tumor Immune Cells  
    Bonnie S Glisson, Jeffrey Myers, N Jr William, Renata Ferrarotto, Head & Neck
  • Join now to see all

Lectures

  • Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mut... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Authored Content

  • Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019August 2020
  • Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019August 2020

Press Mentions

  • MD Anderson Research Highlights: ASCO 2023 Special Edition
    MD Anderson Research Highlights: ASCO 2023 Special EditionMay 25th, 2023
  • Scientists Share ‘Comprehensive’ Map of Volcanoes on Venus — All 85,000 of Them
    Scientists Share ‘Comprehensive’ Map of Volcanoes on Venus — All 85,000 of ThemMarch 28th, 2023
  • Mount Sinai Health System Recognized by Fortune as One of “America’s Most Innovative Companies 2023”
    Mount Sinai Health System Recognized by Fortune as One of “America’s Most Innovative Companies 2023”March 28th, 2023
  • Join now to see all

Professional Memberships

Hospital Affiliations